Advertisement
Home »

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.

Feb 26, 2024

ABOUT THE EXPERTS

  • Claire Kim

    Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Electronic address: Claire_Kim@vrtx.com.

    Mark Higgins

    Vertex Pharmaceuticals Incorporated, Boston, MA, USA.

    Lingyun Liu

    Vertex Pharmaceuticals Incorporated, Boston, MA, USA.

    Nataliya Volkova

    Vertex Pharmaceuticals Incorporated, Boston, MA, USA.

    Anna Zolin

    Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

    Lutz Naehrlich

    Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement